The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksTristel Share News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 452.50
Bid: 445.00
Ask: 460.00
Change: 5.00 (1.12%)
Spread: 15.00 (3.371%)
Open: 447.50
High: 452.50
Low: 447.50
Prev. Close: 447.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Tristel products get approval in US, Canada and South Korea

Thu, 24th Jun 2021 20:31

Tristel PLC - Cambridgeshire-based maker of infection prevention, contamination control and hygiene products - Announces that it has received three regulatory approvals. In the US, gets first approval from the Environmental Protection Agency for its foam-based disinfectant for surfaces in April 2018. In Canada, Tristel's Duo OPH has been approved by Health Canada as a class 2 medical device and is included in Health Canada's Medical Device License Listing. Duo OPH is a high-level disinfectant intended for use on ophthalmic instruments including ultrasound devices and re-usable tonometers and lenses that contact the cornea. In South Korea, Tristel Duo ULT has now been approved as a high-level disinfectant for ultrasound devices, and with Trio will be sold throughout South Korea by HP&C Ltd.

Paul Swinney, CEO of Tristel commented: "Every regulatory approval we achieve represents an important milestone in our progress, and these three approvals are very significant. The enhanced claim set that we have achieved for Jet now justifies taking the product through state-wide registration in the US and gearing up our manufacturing and distribution partnership with Parker Laboratories.

"The approval of Duo OPH by Health Canada represents our first successful registration of a medical device high-level disinfectant in North America. We are actively pursuing a submission to the US FDA for Duo ULT and we are buoyed by this successful application in Canada. The approval in South Korea increases the visibility of our chlorine dioxide technology in the country and extends our distributor's involvement into more clinical areas within a hospital."

Current stock price: 623.00p

Year-to-date change: up 17%

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Oct 2015 09:47

Infection Control Firm Tristel Multiples Dividend As Profit Rises

Read more
12 Oct 2015 05:47

GET READY: Jupiter Fund Management At 0700 BST

Read more
5 Oct 2015 14:59

Earnings, Trading Statements Calendar - Week Ahead

Read more
18 Jun 2015 11:22

LONDON MIDDAY BRIEFING: Eyes Turn To Latest Greek Crisis Meeting

Read more
18 Jun 2015 10:38

WINNERS & LOSERS: Fresnillo, Randgold Resources Up As Gold Price Rises

Read more
18 Jun 2015 07:40

Tristel Shares Rise As It Reveals 3 Pence Special Dividend

Read more
21 May 2015 11:19

LONDON MIDDAY BRIEFING: Royal Mail Outlook Causes Concerns

Read more
21 May 2015 10:45

WINNERS & LOSERS: Miners Boosted By Chinese Stimulus Hopes

Read more
21 May 2015 07:39

Tristel Upgrades Profit Guidance As It Trades Ahead Of Expectations

Read more
25 Feb 2015 08:41

Tristel Raises Dividend 63% After Strong First-Half Profit Rise

Read more
11 Nov 2014 09:57

Tristel Says Another Study Has Shown Benefits Of Its Wipes Study

Read more
4 Nov 2014 15:16

Tristel chairman Soler trims stake

The chairman of hospital infection control experts Tristel sold a small chunk of his shares in the company late on Monday. Francisco Soler sold 250,000 shares in the dividend-paying company at a price of 75p per share on 31 October and on 3 November 2014 sold 100,000 more at the same price to gross

Read more
3 Nov 2014 18:08

DIRECTOR DEALINGS: Tristel Non-Executive Chairman Sells Shares

Read more
13 Oct 2014 14:46

Tristel boosts full-year profit after restructuring

Tristel, a manufacturer of infection prevention and contamination control products, saw profit for the year to end of June rise after undertaking a set of restructuring measures. An 18-month restructuring plan, the creation of new products and investment in the disinfection market led the firm to be

Read more
13 Oct 2014 09:23

Tristel Quadruples Dividend As It Swings To Profit On Restructuring

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.